Clinical trial · Observational
A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer
A Real-World Retrospective Cohort Analysis of SMARCA4-Deficient Advanced Lung Cancer
NCT07121387CI-TRIAL-00093590completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC (Advanced Non-small Cell Lung Cancer) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
| SMARCA4-Deficient Tumor | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- SMARCA4-Deficient group
- label
- SMARCA4-Intact group
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- 5 years
- description
- Time from the beginning of first-line therapy to the first progression (PD) in patients with lung cancer
Secondary outcomes (3)
- measure
- Overall survival (OS)
- timeFrame
- 5 years
- description
- Overall survival (OS) is defined as the duration from the beginning of first-line therapy until death due to any cause. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with stage III-IV NSCLC according to the American Joint Committee on Cancer staging criteria (7th edition); * Lesions are measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; * Receiving first-line immunotherapy or chemotherapy as anti-tumor treatment. Exclusion Criteria: * SMARCA4 gene test was not performed; * Not receive treatment; * Lost to follow-up after one treatment cycle.
References
Publications (0)
Data not yet available
No reference posted for this study.